Clinical Trial

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-06-24; most recent amendment 2026-05-25.
Trial Details
NCT Number NCT07048197
Lead Sponsor Novartis Pharmaceuticals
Conditions Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
Enrollment 27 participants
Start Date 2025-06-20
Primary Completion 2028-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-27